Refine by MP, party, committee, province, or result type.
Health committee It would be nice if IRAP were peer reviewed.
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee Oh, great. Thanks. To me, the most important thing would be to break down the barriers between disciplines and encourage a multidisciplinary approach. I think that is crucial to product development. I don't know how to do that, but if I could wave my magic wand that you have bes
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee As I mentioned, I would like one of the granting councils to claim them as their own and to put in place a number of studentships, or scholarships, or post-doctoral fellowships to do this. I also think that it would be very nice if we set up post-doctoral fellowships in industry,
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee I'll let you take that one.
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee Certainly we need more capital from venture capitalists, and we need them to be willing to take risks, and to be more knowledgeable in assessing the material that is presented to them. How best to go about that, I'm not really sure. What tends to motivate venture capitalists is
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee Yes, that's the phase three human trial.
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee Yes, we did. We did an IPO. This was in 1995. We did an IPO, and we traded on the TSX and the NASDAQ. Right now, as an exit strategy for biotechs, no one is doing an IPO anymore. You just hope to be bought up by a bigger company.
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee I would fully agree with that. We didn't say we wanted more money. We said that it would be nice if we could better focus it such that the work being done is converted to products. Strategies would be a good start. I'm not asking to pour more money into the existing system, just
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee What I mentioned was that we have a shortage of medicinal chemists. A medicinal chemist is a chemist who makes molecules. All drugs are molecules, but not all molecules are drugs, and it takes people with a subset of interests to be able to identify those. As mentioned, we actua
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee The countries that exceeded were the United States, Japan, Germany, and Switzerland. They were the main ones that exceeded. These are countries which have a strong industrial pharmaceutical sector that can take discoveries and convert them to products. So, yes, there were a numbe
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee I'll answer it in two ways. First of all, they have particular programs in place that fund medicinal chemistry, which actually fund drug discovery. It's not tacked on to some other particular funding agency. As already mentioned, for example, in the United States they have SBIR
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee MaRS is an interesting idea and there are many aspects of MaRS that I like. Other times I think it's from Venus. Within MaRS, we have the example of the university hospitals at the University of Toronto also working with the university. I always liked that. University hospitals,
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee Yes.
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee That's a dangerous thing. I would hate to think that the research budget has x number of dollars in it, and so to solve the problem we're going to take all the money from the basic science people and whip it over to the applied people. The end result is that we'll just gut basic
October 30th, 2012Committee meeting
Dr. Donald Weaver
Health committee Sure. Since I interact with the pharmaceutical industry a lot, I get to see it. The pharmaceutical industry will have biologists, chemists, and biochemists in the same building. When you, as a biologist, have a problem that needs a chemist's answer, you go down the hall and spea
October 30th, 2012Committee meeting
Dr. Donald Weaver